Document:

EX-10.9

 Exhibit 10.9 

FIFTH ADDENDUM 
 TO THE
RESEARCH AND LICENSE AGREEMENT 
 This Fifth Addendum to Research and License Agreement (the” Fifth Addendum”} is made by and between
The Technion Research & Development Foundation Ltd. (“TRDF”) and Eloxx Pharmaceuticals Ltd. (“Eloxx”). 

WHEREAS, TRDF and Eloxx are parties to Research and License Agreement with an effective date of August 29· 2013, as amended on
November 26, 2013, January 14, 2014, June 9, 2014, August 3 , 2014, January 21, 2015, February 9 2015 and April 29, 2015 (collectively, the “Agreement”); and 

WHEREAS, the parties desire to continue the relationship contemplated by the Agreement and to further amend the Agreement as set forth herein;

 Now, THEREFORE, the parties hereby agree as follows: 
  

	1.	Unless otherwise defined herein, capitalized terms used in this Fifth Addendum shall have the meanings assigned thereto in the Agreement. 

 

	2.	The last sentence of Section 3.1.4 to the Agreement shall be revised as follows: 

“[...] For clarity, this Section 3.1.4 does not apply to any Research Inventions, to any Research Results nor to
any Patent Rights claiming Research Inventions or Research Result, but will apply with respect to any rights, title and interest in and to the patents listed in Exhibit F attached hereto.”. 

 

	3.	Except as added herein, all other terms and conditions of the Agreement shall remain in full force and effect, as relevant to this Fifth Addendum. 

 

	4.	This Fifth Addendum may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Any signature page delivered by facsimile or
electronic image transmission shall be binding to the same extent as an original signature page. 

 IN WITNESS
WHEREOF, the parties hereby accept and agree to the terms and conditions of this Fifth Addendum. 
  

									
	ELOXX PHARMACEUTICALS LTD.	 		  	THE TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD.
					
	By:	 	 /s/ Silvia Norman
	 		  	By:	 	 /s/ Benjamin Soffer

					
	Name:	 	Silvia Norman	 		  	Name:	 	Benjamin Soffer
					
	Title:	 	CEO	 		  	Title:	 	Technology Transfer Office, Manager
					
	Date:	 	2/6/2015	 		  	Date:	 	23.7.15

  
 Confidential 

 ASSIGNMENT 

For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned (hereinafter called the
”Assignor’’): 
 Technion Research & Development Foundation Limited 

Senate House, Technion City 

3200004 Haifa 

Israel 
 hereby sell(s),
assign(s) and transfer(s) to: 
 Eloxx Pharmaceuticals Ltd, 

14 Sbenkar Street 
 4672514 Herzlia 

Israel 
 (hereinafter called the “Assignee”),
its successors, assigns, nominees or other legal representatives, the undersigned’s entire rights, title and interest in and to the invention titled: 

USE OF AMINOGLYCOSIDE ANALOGS IN THETREATMENT OF RETT 

SYNDROME 
 described and claimed in the
following Patent Application: 
 US Provisional Patent Application No. 6:2/008,028, 

filed on June 5; 2014, 

and identified as Attorney Docket No. 595:29 

and in and to said Patent Application, and all original and reissued Patents granted therefore, and all divisions and continuations thereof, any corresponding
PCT Patent Application and the National Phases thereof, including the right to apply and obtain Patents in all other countries, the right to claim priority under International Conventions, and the Letters Patent which may be granted thereon: 

covenant that the undersigned have (has) the full right to convey the entire interest therein assigned; 

authorize(s) and request(s) the Registrar of Patents, and any Official of any country whose duty it is to issue Patents on applications as aforesaid, to issue
the said Letters Patent to the said Assignee; 
 and agree(s) to sign all lawful papers, make all rightful oaths, do all lawful acts requisite for such
Patent Applications, and do everything possible to aid said Assignee to apply for, obtain and enforce Patent protection for said invention. 
  

													
	ASSIGNOR	 		 	ASSIGNEE
			
	        Technion Research & Development foundation Limited	 		 	        Eloxx Pharmaceutical Ltd.
							
	Signature	 	:	 	 /s/ Benjamin Soffer
	 		 	Signature	 	:	 	 /s/ Silvia Norman

							
	Name	 	:	 	Benjamin Soffer	 		 	Name	 	:	 	Silvia Norman
							
	Capacity	 	:	 	Technology Transfer Office, Manager	 		 	Capacity	 	:	 	CEO
							
	Date	 	:	 	June 2, 2015	 		 	Date	 	:	 	2/6/15

  
 Confidential 

							
	Signature	 	:	 	 /s/ Wayne D. Kaplan
	 	
				
	Name	 	:	 	Wayne D. Kaplan	 	
				
	Capacity	 	:	 	Executive Vice President for Research	 	
				
	Date	 	:	 	June 2, 2015	 	

  
 3EX-10.10

 Exhibit 10.10 

Confidential 
 Execution Copy 

SIXTH ADDENDUM 
 TO THE
RESEARCH AND LICENSE AGREEMENT 
 This Sixth Addendum to Research and License Agreement (the “Sixth Addendum”) is made by and between
The Technion Research & Development Foundation Ltd. (“TRDF”) and Eloxx Pharmaceuticals Ltd. (“Eloxx”). 

WHEREAS, TRDF and Eloxx are parties to a Research and License Agreement with an effective date of August 29· 2013, as amended on November 26,
2013, January 14, 2014, June 9, 2014, August 3, 2014, January 21, 2015, February 9, 2015, April 29, 2015 and June 2, 2015 (collectively, the “Agreement”); and 

WHEREAS, the parties desire to continue the relationship contemplated by the Agreement and to further amend the Agreement as set forth herein; 

Now, therefore, the parties hereby agree as follows: 
  

	1.	Unless otherwise defined herein, capitalized terms used in this Sixth Addendum shall have the meanings assigned thereto in the Agreement. 

 

	2.	Subject to the terms and conditions contained herein and in the Agreement, TRDF hereby assigns to Eloxx all rights and title in and to the patents listed in Exhibit A attached hereto (the “Assigned
Patents”). Eloxx hereby undertakes not to further assign and/or transfer the Assigned Patents nor incur any lien or other encumbrance upon the Assigned Patents, except in accordance with the terms and provisions of the Agreement, including,
inter alia, Section 14.10. It is hereby clarified that such assignment shall not change the terms of the license granted to Eloxx with respect to such Assigned Patents nor shall it relieve or derogate from TRDF’s rights to receive
royalties for such Assigned Patents in accordance with the terms of the Agreement. 

  

	3.	Upon termination of the Agreement, for any reason, such rights and title with respect to the Assigned Patents shall be promptly delivered and assigned back to TRDF without the need for any notice or additional action by
TRDF. Any existing agreements that contain a sublicense of the Assigned Patents shall be treated according to the provisions of Section 12.3.1 to the Agreement. If and to the extent any additional action is required from Eloxx in order to
perfect or enforce or effectuate the title and interest therein, as described above, including to effect or confirm the formal transfer thereof to TRDF, during and after the term of the Agreement, Eloxx shall fully cooperate with TRDF and shall take
any and all necessary or desirable actions immediately upon the request of TRDF and shall provide any and all assistance, including the preparation or execution, as applicable, of documents, declarations, assignments and other data required to
effectuate the assignment back of the title and interest therein. Eloxx shall bear the expenses of the assignment and assignment back to the extent there are any. 

If TRDF is unable for any reason to secure Eloxx’s signature to or to apply for the assignment back of the Assigned Patents, then Eloxx
hereby irrevocably designates and appoints TRDF and its duly authorized officers, agents and assigns as its agent and attorney in fact, to act for and on its behalf and stead to execute and file any such applications and to do all other lawfully
permitted acts to further the assignment back, including without limitation the prosecution and issuance of letters patent or copyright registrations thereon, with the same legal force and effect as if executed by Eloxx. 

 

	4.	Eloxx shall be responsible and shall bear all costs for the preparation, filling, prosecution, protection of the Assigned Patents using independent patent counsel reasonable to TRDF. Eloxx shall: (a) instruct such
patent counsel to furnish TRDF with copies of all correspondence relating to the Assigned Patents from the United States Patent and Trademark Office (USPTO) and any other patent office, as well as copies of all proposed responses to such
correspondence in time for TRDF to review and comment on each such response; (b) give TRDF an opportunity to review the text of each patent application before filing; (c) consult with TRDF with respect thereto; (d) supply TRDF with a
copy of the application as filed, together with notice of its filing date and serial number; and (e) keep TRDF advised of the status of actual and prospective patent filings. 

 

	5.	Should Eloxx decide it does not wish to bear the costs for the preparation, filing, prosecution and protection of the Assigned Patents, Eloxx shall immediately assign such patents back to TRDF, but in any event at least
sixty (60) days prior to the applicable deadline for the filing of an application or responding to an office action regarding such application and/or patent. 

  
 Confidential 

 Confidential 
  

	6.	Except as added herein, all other terms and conditions of the Agreement shall remain in full force and effect. 

  

	7.	This Sixth Addendum may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Any signature page delivered by facsimile or
electronic image transmission shall be binding to the same extent as an original signature page. 

 IN WITNESS
WHEREOF, the parties hereby accept and agree to the terms and conditions of this Sixth Addendum. 
  

									
	ELOXX PHARMACEUTICALS LTD.	 		 	THE TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD.
					
	By:	 	 /s/ Silvia Noiman
	 		 	By:	 	 /s/ Benjamin Soffer

					
	Name:	 	Silvia Noiman	 		 	Name:	 	Benjamin Soffer
					
	Title:	 	CEO	 		 	Title:	 	
					
	Date:	 	11 January 2016	 		 	Date:	 	January 20, 2016

  
 Confidential 

 Confidential 

Exhibit A 
  

																	
	AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS [design around of Gen 3]
	 Our Ref

Client Ref
	  	Country	  	Earliest
Priority	  	Entry
Date	  	Filing Date
Application No.	  	Publication Date + No.
Issue Date + Patent No.	  	Next Action	  	 Status
	  	Assignee
Inventor
	59536	  	USA
PRO	  		  		  	02-Sep-2015
 62/213,143
	  		  	Foreign Filing Due
 02-Sep-2015
	  		  	Eloxx Pharmaceuticals Ltd.
 BAASOV Timor

  

																	
	AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS [design around of Gen 3]
	 Our Ref

Client Ref
	  	Country	  	Earliest
Priority	  	Entry
Date	  	Filing Date
Application No.	  	Publication Date + No.
Issue Date + Patent No.	  	Next Action	  	 Status
	  	Assignee
Inventor
	59535	  	USA
PRO	  		  		  	02-Sep-2015
 62/213,187
	  		  	Foreign Filing Due
 02-Sep-2016
	  		  	Eloxx Pharmaceuticals Ltd.
 BAASOV Timor

 AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS US Provisional Patent Application
No. 62/274,915 

  
 Confidential

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00281-of-00352.parquet"}]]